One of the most persistent challenges in gene and cell therapy is not simply delivering a therapeutic gene to the right cell — it is ensuring that, once delivered, the gene’s expression can be turned on and off with sufficient precision to remain both safe and effective over time. Current inducible systems, which allow researchers…
Base-Edited CAR T-Cell Therapy Achieves Remission in Refractory T-Cell Leukemia The therapeutic armamentarium against hematological malignancies has been substantially enriched through the clinical implementation of BE-CAR7, a pioneering base-edited chimeric antigen receptor T-cell therapy targeting T-cell acute lymphoblastic leukemia. Announced this December by investigators at University College London and Great Ormond Street Hospital, this therapeutic…